Skip to main content
. 2017 Sep 4;1:28. doi: 10.1038/s41698-017-0032-z

Table 3.

Targeted therapies in lung cancer

Target gene Alteration Drug type Candidate
EGFR Amplification EGFR inhibitor Gefitinib, erlotinib, afatinib, osimertinib, olmutinib
ALK Translocation/mutation ALK inhibitor Crizotinib, alectinib, ceritinib
MET Amplification MET/ROS1 inhibitor Crizotinib, cabozantinib
RET Amplification/mutation
ROS1 Fusion
PD-L1 PD-1 inhibitor Nivolumab, pembrolizumab
HER2 Amplification HER2 inhibitor Trastuzumab, afatinib, dacomitinib
BRAF Amplification/mutation BRAF inhibitor Vemurafenib, dabrafenib